From Molecule to Disease: PIPs Project of the Leibniz Cooperative Excellence Launched

What role do certain lipids, known as phosphoinositides (PIPs), play in obesity and other metabolic diseases? This is now being investigated by scientists from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), and the Leibniz-Institut für Analytische Wissenschaften (ISAS) in a joint project.

Before we proceed with FAQ, a basic background information about phosphoinositides (PIPs) is necessary.

Phosphoinositides (PIPs) are a type of lipids or fats that play a significant role in several cellular functions. These include cell growth, cell division, protein trafficking and lipid signaling. Lipid signaling refers to the processes where lipids participate in transmitting signals through the cells, playing an essential part in controlling various biological responses.

FAQ:
1. Q: What is being researched in this project?
A: The PIPs Project of the Leibniz Cooperative Excellence aims to study the role of certain lipids called phosphoinositides (PIPs) in obesity and other metabolic diseases.

2. Q: Which organizations are involved in this research?
A: The key organizations involved are the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), and also Leibniz-Institut für Analytische Wissenschaften (ISAS).

3. Q: Why are these specific lipids – Phosphoinositides being examined for Obesity?
A: Phosphoinositides play an essential role on different cellular processes including growth and division of cells, transportation of protein inside cells and lipid signalling which could have potential impacts on metabolism as well as fat accumulation.

4. Q: What can be expected out of this research project?
A: This joint initiative by premier Institutes could bring new insights into understanding obesity’s biochemical mechanisms better with implications for easier diagnosis or development more targeted treatments..

5.Is there any detail provided about when we can expect some findings from this research?
A.No specific timeline has been mentioned about when results will be publicly available however since it is an extensive study, it’s expected that it will take multiple years.

6. How can I stay updated about the progress of this research?
A: For regular updates, you can keep an eye on the official news sections of participating Institutes or follow the provided link to the press release.

7. Q: Can this research help find a cure for obesity and other metabolic diseases?
A: While an outright cure may not be immediate, a greater understanding of how PIPs interact with obesity and metabolic diseases could lead to development of novel therapies that are more effective against these conditions.

8. Q: Is there any precedence for such molecular level examination leading to breakthrough treatment strategies?
A. Yes there have been several instances in history where better understanding at molecular level has paved way for targeted and more effective drug development initiatives, though it’s important note – such efforts often require substantial time before becoming applicable clinically.

Originamitteilung:

What role do certain lipids, known as phosphoinositides (PIPs), play in obesity and other metabolic diseases? This is now being investigated by scientists from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), and the Leibniz-Institut für Analytische Wissenschaften (ISAS) in a joint project.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Uniklinik Köln stellt CAR-T-Zellen selbst her – Herstellungserlaubnis für erstes Klinikum in NRW erteilt

Seit 2018 sind in der EU sechs verschiedene CAR-T-Therapien zugelassen. Sie werden aktuell gegen einige Blutkrebsarten, Tumore der Lymphdrüsen und des Knochenmarks eingesetzt. Diese Zelltherapeutika werden in Laboren der Pharmaunternehmen in den USA und vermehrt auch in Europa hergestellt und in speziell dafür qualifizierten Kliniken den Patienten verabreicht. Die Wartezeit auf diese CAR-T-Zellen dauert zwischen vier und acht Wochen. Deutlich schneller geht es, wenn die Herstellung der CAR-T-Zellen direkt vor Ort in der Klinik erfolgt. Dies verkürzt die Wartezeit für die Patienten auf weniger als zwei Wochen und vermeidet Transportwege quer durch Europa oder in die USA.

Read More

Deutsches Reanimationsregister der DGAI: Mit neuer Analyse wird Defibrillator zum „Fahrtenschreiber der Reanimation“

Nürnberg. Das Deutsche Reanimationsregister, das unter der Trägerschaft der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI) steht, startet mit einer wegweisenden Neuerung ins Jahr 2025: Das Gerätedatenmodul wurde um eine neue Funktion zur Gerätedatenanalyse erweitert. Diese Neuerung ermöglicht eine automatisierte Auswertung relevanter Daten aus der prähospitalen Versorgung und trägt so zu einer optimierten Notfallversorgung bei Patientinnen und Patienten mit Herz-Kreislauf-Stillstand bei.

Read More